바로가기  >

Abstract
BACKGROUND/AIM:
To validate the effect of treatment intensification on survival in esophageal squamous cell carcinoma (ESCC) patients undergoing definitive concurrent chemoradiotherapy (dCCRT).

PATIENTS AND METHODS:
We reviewed the medical records of 73 ESCC patients who underwent dCCRT between 2006 and 2017 in 3 institutions.

RESULTS:
The median follow-up time was 13.3 months. The median overall survival (OS) and locoregional recurrence-free survival (LRFS) were 13.3 and 11.2 months, respectively. The median radiotherapy dose was 55.8 Gy, and the median biologically effective dose (BED) was 65.8 Gy. Chemotherapy was given in all patients during dCCRT, and adjuvant chemotherapy was administered in 56 patients (76.7%). Adjuvant chemotherapy improved OS (3-year, 24.2% vs. 11.8%, p=0.004). Higher BED ≥70 Gy improved LRFS (3-year, 41.7% vs. 23.6%, p=0.035).

CONCLUSION:
The addition of chemotherapy after dCCRT improves OS. A higher radiotherapy dose improved LRFS, but not OS. Adjuvant chemotherapy should be considered after dCCRT for better outcomes.

Author information

Koh HK1, Park Y2, Koo T3, Park HJ4, Lee MY5, Chang AR2, Hong S1, Bae H5.
1
Department of Radiation Oncology, Konkuk University School of Medicine and Konkuk University Medical Center, Seoul, Republic of Korea.
2
Department of Radiation Oncology/CyberKnife Center, Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea.
3
Department of Radiation Oncology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Gyeonggi-do, Republic of Korea kootaeryool@hallym.or.kr.
4
Department of Radiation Oncology, Hanyang University College of Medicine, Seoul, Republic of Korea.
5
Department of Radiation Oncology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Gyeonggi-do, Republic of Korea.